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Abstract Survival outcomes following multimodal treat-
ment of operable oesophageal and gastrooesophageal
cancer remain disappointingly poor. Although an appre-
ciation of the impact of both tumour location and his-
tological subtype is now shaping the design of clinical
trials, there has been a lack of consensus of the optimal
neoadjuvant treatment strategy. This update article will
review recent advances in the use of both neoadjuvant
chemotherapy and chemoradiotherapy. The emerging
role of PET imaging to direct appropriate neoadjuvant
treatment regimens and the additive benefit of biological
agents are also discussed.
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Introduction
Approximately 450,000 new cases of oesophageal cancer
are diagnosed each year worldwide, making it the eighth
most common cancer [1]. Although squamous cell carci-
noma (SCC) is the most common variant, there is geo-
graphical variation in the incidence of the two major his-
tological subtypes. The number of patients diagnosed with
adenocarcinoma has increased during the last few de-
cades, particularly in Western countries, and is felt to re-
flect the rise in obesity rates and gastrooesophageal reflux
disease [2, 3]. Adenocarcinoma typically affects the lower
oesophagus and gastrooesophageal junction (GOJ) and
likely represents a separate disease entity to squamous
cell tumours, which are more common in the upper and
middle third of the oesophagus.
Long-term outcomes for oesophageal cancer remain poor
with 5-year overall survival (OS) rates of only around 20%,
and the majority of patients treated with curative intent even-
tually succumb to their disease [4]. Patients deemed to have
potentially resectable disease are offered a multimodal ap-
proachwith either neoadjuvant or perioperative chemotherapy
or neoadjuvant chemoradiotherapy. The rationale for periop-
erative therapy is to treat occult micrometastases, and to in-
crease the likelihood of a complete surgical resection (R0
resection) and pathological complete response (pCR).
Historically studies have included oesophageal, GOJ and
gastric tumours of both SCC and adenocarcinoma subtypes.
These specific subgroups are important in the management of
oesophageal cancer, as reflected by the design of more recent
trials. This review will summarise the current evidence for
neoadjuvant chemotherapy in both histological subtypes, peri-
operative chemotherapy in adenocarcinoma of the oesopha-
gus/GOJ, and neoadjuvant chemoradiotherapy (nCRT). The
role of PET imaging in guiding neoadjuvant treatment
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strategies and the use of novel biological agents is also
discussed. Table 1 summarises ongoing neoadjuvant trials in
oesophageal cancer.
Neoadjuvant Chemotherapy in Oesophageal Cancer
(both Adenocarcinoma and SCC Histologies)
There has been a lack of international consensus regarding the
role of neoadjuvant chemotherapy for oesophageal cancer fol-
lowing results from conflicting large randomised trials.
Practice in the UK was largely dictated by the outcomes of
the MRC OE02 trial, which compared 2 cycles of cisplatin
and 5-fluorouracil followed by surgery to surgery alone, with
a 6% improvement in 5-year OS rates (23 vs 17%) [5, 6].
Tumours were smaller, less locally invasive following neoad-
juvant chemotherapy, with lower rates of lymph node positiv-
ity, and significantly higher rates of R0 resection compared to
those in the surgery-alone arm. Nine percent of patients in
both arms received neoadjuvant radiotherapy but this did not
influence outcomes in subgroup analysis.
In contrast, the RTOG 8911 trial failed to identify any sur-
vival advantage or difference in R0 rates for neoadjuvant
cisplatin/5-fluorouracil versus surgery alone [7]. Differences
with OE02 include the use of three neoadjuvant cycles with a
longer time to surgery, a higher dose of cisplatin and the use of
postoperative chemotherapy for stable disease/responders
(with 52% of patients receiving at least 1 cycle of adjuvant
chemotherapy) [8]. Analysis for histological subtype did not
identify a difference in survival outcomes, but subsequent
analysis of the long-term results did confirm that an objective
response to neoadjuvant chemotherapy was associated with
significantly better OS than that of non-responders or patients
receiving surgery alone [7].
Two recent meta-analyses have confirmed the survival ben-
efit for neoadjuvant chemotherapy over surgery alone [9, 10•].
The first meta-analysis of 17 trials found a survival benefit of
5.1% at 2 years (HR 0.87) (95% CI 0.79–0.96; P = 0.005) [9].
Analysis according to histological subtype showed only pa-
tients with adenocarcinoma (HR 0.83; 95% CI 0.71–0.95;
P = 0.01) and not SCC (HR 0.92; 95% CI 0.81–1.04;
P = 0.18) had a statistically significant improvement in OS
with neoadjuvant chemotherapy. This is in contrast to the
OE02 trial which did not observe a survival difference accord-
ing to histological subtype, and neoadjuvant chemotherapy is
regarded as an option for both SCC and adenocarcinoma tu-
mours in the UK.
The Cochrane meta-analysis of over 2000 patients with
localised, potentially resectable thoracic oesophageal carcino-
ma found that the use of cisplatin-based neoadjuvant chemo-
therapy reduced the risk of death by 12% at 5 years (HR 0.88,
95% CI 0.80–0.96; P = 0.003) [10•]. Furthermore, R0 resec-
tion rates were significantly higher in patients receiving
chemotherapy compared to surgery alone, although both local
and distant recurrence rates did not significantly differ be-
tween the two groups. Whilst preoperative chemotherapy
was associated with mortality and toxicity, the authors did
not find that the latter equated to a higher rate of postsurgical
complications. They noted that significant study heterogeneity
exists in terms of the chemotherapy regimens used, provision
of adjuvant chemotherapy, and inclusion of patients with tu-
mours of both histological subtypes and also the quality of
included trials. The conclusion is that the evidence to date
for neoadjuvant chemotherapy is only of moderate quality
for thoracic oesophageal cancer.
Perioperative Chemotherapy for Adenocarcinoma
of the Lower Oesophagus and GOJ
The efficacy of perioperative chemotherapy for resectable ad-
enocarcinoma of the lower third of the oesophagus, and GOJ
was established in the MAGIC trial [11]. Six cycles of
epirubicin, cisplatin and 5-fluorouracil (ECF; 3 cycles admin-
istered before and after surgery, qd21) improved both OS and
PFS in over 500 patients, with a 5-year survival rate of 36%
compared to 23% for surgery alone. Downstaging and R0
rates were also superior with ECF, as were local and failure
rates. This was despite 45% of patients in the perioperative
chemotherapy arm not receiving any postoperative treatment.
Initially only patients with operable gastric carcinoma were
eligible for inclusion; in light of the increasing incidence of
GOJ adenocarcinoma, patients with lower third oesophageal
tumours were later included but only constituted 26% of the
population which may limit the applicability of the results to
oesophageal cancer patients. Perioperative cisplatin/5-
fluorouracil has also shown similar survival benefits and im-
proved R0 rates compared with surgery alone in a smaller trial
of predominantly gastrooesophageal adenocarcinoma [12].
Both regimens are now standard treatment options.
Several groups have investigated different combination
chemotherapy regimens in phase II studies in an attempt to
improve response rates and survival outcomes in locally ad-
vanced resectable gastrooesophageal adenocarcinoma. Three
cycles of DCF (docetaxel, cisplatin, 5-fluorouracil) before and
after surgery resulted in all (n = 41) patients achieving a R0
resection with a 10% pCR rate, and 3-year survival of 60%
[13]; docetaxel, cisplatin and capecitabine (DCX) has shown
similar response rates, with 60% of patients achieving T-stage
downstaging and 40% of node-positive patients converting to
N0 status [14]. Only around half of patients completed post-
operative treatment with both of these taxane-based regimes,
most often due to patient choice or fitness.
In the German FLOT4 trial, 714 patients with locally ad-
vanced resectable gastric and GOJ tumours were randomised
between perioperative FLOT (5-fluorouracil, leucovorin,
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oxaliplatin and docetaxel, 4 + 4 cycles, qd14) and ECF/ECX.
The study demonstrated a 10% increase in pCR rates in favour
of the FLOT arm (15.6% versus 5.8%, P = 0.015); survival
outcomes are awaited [15]. FLOT is a feasible regimen in
patients over the age of 65 years, however caution is required
in selecting the patients most likely to benefit due to higher
toxicity rates compared to those seen with perioperative FLO
[16].
Concerns exist regarding increased grade 3/4
chemotherapy-related toxicities, namely neutropenia and
mucositis, with taxane-based treatment. However, it is
argued that these are manageable with appropriate
dose-reductions and prophylactic G-CSF, and may be
off-set by the early improvements in dysphagia with
such regimens and avoidance of anthracycline-induced
cardiotoxicity [13, 14]. Furthermore, postsurgical com-
plications (around 40%) and mortality rates do not ap-
pear to be increased; further studies are warranted.
Neoadjuvant Chemotherapy for Adenocarcinoma
of the Lower Oesophagus and GOJ
Extended neoadjuvant chemotherapy as an alternative to peri-
operative treatment has been proposed as a strategy to avoid
the need for postsurgical treatment. Four cycles of ECX
(epirubicin, cisplatin and capecitabine) was compared to 2 cy-
cles of cisplatin/5-fluorouracil prior to surgery in the UK
OE05 trial which included over 800 patients. Three-year OS
rates did not significantly differ at 42 and 39%, respectively
(HR 0.92, 95% CI 0.79–1.08; P = 0.3017) [17•]. There was a
suggestion that ECX improved R0 resection rates and the
likelihood of pCR, and although PFS and DFS were both
longer in the ECX arm, statistical significance was not met.
ECX caused more grade 3/4 chemotherapy-related toxicity,
however postsurgical complication and mortality rates did
not differ significantly between treatment arms.
The NeoFLOTwas a single centre, non-randomised phase
II trial where 6 cycles FLOTwere administered every 14 days
(n = 50) prior to surgery in T3/T4 or node positive tumours of
the GOJ or stomach [18]. The regimen was well tolerated
(main grade 3/4 toxicities included neutropenia, diarrhoea
and mucositis), 86% of patients achieved a R0 resection and
a 1-year survival rate of 79% was observed. The authors re-
ported that in those achieving either a pCR or near pCR
(40%), the majority of patients had intestinal type tumours.
Neoadjuvant Chemotherapy for SCC
SCC is the predominate histological subtype in Asia
where the standard of care for stage II-III disease is
neoadjuvant chemotherapy followed by transthoracic
oesophagectomy and lymphadenectomy. The JCOG
9907 trial randomised patients to 2 cycles of cisplatin/
5-fluorouracil either before or after surgery; 5-year OS
rates were 55 versus 43%, respectively (HR 0.73, 95%
CI 0.54–0.99, P = 0.04), with no significant differences
in adverse events between the groups [19, 20].
Interest has recently developed in the potential addi-
tive benefit of taxanes following promising Asian phase
II feasibility studies in oesophageal SCC and known
benefits in head and neck SCC. Perioperative weekly
nab-paclitaxel and cisplatin achieved 100% R0 rates
and both OS and DFS were significantly longer in pa-
tients who were downstaged (63%) compared to those
not downstaged [21].
In a trial of 42 patients, impressive 2-year OS and PFS rates
of 88 and 75%, respectively were reported with DCF when
compared to standard cisplatin/5-fluorouracil [22•]. Over 90%
of patients completed at least 2 cycles of neoadjuvant treat-
ment and achieved R0 resection, despite a large proportion of
patients (42%) requiring dose reductions after the first cycle.
The overall response rate was 64% according to RECIST
criteria with a pCR rate of 17%. Despite 83% of patients
developing grade 3–4 neutropenia, only 2% had febrile neu-
tropenia; all patients received prophylactic antibiotics but not
G-CSF as standard. There were no treatment-related deaths,
although overall perioperative complication rates were higher
compared to standard cisplatin/5-fluorouracil. A second
smaller feasibility study also showed DCF efficacy in this
setting [23]; 93% of patients achieved a curative oesophageal
resection with a similar toxicity profile, although higher rates
of febrile neutropenia were noted at 18%.
The Japanese JCOG1109 NExT three-arm phase III study
is comparing neoadjuvant cisplatin/5-fluorouracial to
neoadjvuant DCF and to neoadjvuant chemoradiotherapy
(concurrent cisplatin/5-fluorouracil, 41.4Gy in 23 fractions
over 5 weeks) in SCC of the thoracic oesophagus [24]. The
primary end-point is OS, with secondary measures including
PFS, pCR/R0 resection rates and toxicities, with the aim of
identifying the optimal neoadjuvant treatment strategy in this
subgroup.
Neoadjuvant Chemoradiotherapy (nCRT)
Stage I and II oesophageal cancers are unlikely to re-
quire neoadjuvant or perioperative treatment. Indeed,
outcomes may be worse because of the morbidity and
mortality associated with multimodality treatment [25•].
More locally advanced tumours benefit from neoadju-
vant therapy compared to surgery alone [9]. There have
been several trials comparing nCRT to surgery alone in
oesophageal cancer. However, most of these trials were
c ommen c e d i n t h e 1 9 8 0 s a n d 1 990 s , w e r e
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underpowered, and there was significant heterogeneity
in chemotherapy, radiation doses and surgical technique
[26–31]. Unsurprisingly results have been mixed. A
2003 meta-analysis of these trials concluded that OS at
3 years was improved (OR 0.66, CI 0.47–0.92;
P = 0.016) in the nCRT arms but with the cost of
increased all treatment mortality (OR 1.63, CI 0.99–
2.68; P = 0.053) [32]. A further meta-analysis including
trials from 1960 to 2007, concluded that in spite of the
significant heterogeneity, nCRT increases 3 year OS ver-
sus surgery alone with a number needed to treat (NNT)
of 10. There was an increased morbidity and mortality
with a number needed to harm (NNH) of 25 [33].
Therefore, on balance, the benefit outweighs the risk
for appropriately selected patients.
The German POET study, which sought to establish
the superiority of chemoradiation over chemotherapy,
closed early due to poor accrual and was significantly
underpowered as a result [34]. Patients with locally ad-
vanced adenocarcinoma of the EGJ were randomised to
either neoadjuvant cisplatin/5-fluorouracil chemotherapy
over 15 weeks followed by surgery or 12.5 weeks of
induction chemotherapy (cisplatin/5-fluorouracil) follow-
ed by nCRT (cisplatin and etoposide, 30Gy in 15 frac-
tions over 3 weeks) and then surgery. Its results showed
a non-significant trend in favour of CRT improving sur-
vival relative to chemotherapy, but postoperative mortal-
ity was higher in the CRT arm.
In 2012, the randomised phase III trial CROSS, established
the modern precedent for chemoradiotherapy in the preopera-
tive treatment of oesophageal cancer [35]. Patients were ran-
domly assigned to surgery alone or neoadjuvant treatment
with weekly carboplatin (AUC2) and paclitaxel (50 mg/m2)
given concurrently with 41.4 Gy in 23 fractions of radiation.
Median overall survival was more than doubled from 24 to
49 months in patients treated with tri-modality therapy, R0
resections improved as did pCR rates, a benefit which
persisted in long-term follow-up [36••]. Adverse events were
low, with no increase in postoperative mortality.
The benefit of the CROSS protocol is most pronounced in
the squamous cell subgroup. Patients with SCC performed
significantly better with a median survival of 81 months com-
pared to 43 months for adenocarcinoma of the oesophagus.
Proponents of chemotherapy alone argue that for adenocarci-
noma these data are nomore persuasive than theMAGIC trial.
In the adenocarcinoma subgroup of CROSS, the 5 year OS for
CRT and surgery was 47%, compared to 33% in the surgery
alone group [36••]; this is similar to the 13% absolute benefit
for chemotherapy seen in MAGIC, although the OS rate for
surgery only patients in this study was lower at 23% [11]. The
ongoing Neo-AEGIS trial, which is randomising patients with
operable oesophageal and GOJ adenocarcinoma between the
CROSS regimen and perioperative ECX (as in the MAGIC
trial), may provide the definitive answer of which regimen to
use [37], but until then recommendations are likely to vary.
Induction Chemotherapy prior to nCRT
Other attempts to improve response rates include induc-
tion chemotherapy prior to neoadjuvant chemoradiother-
apy. Two cycles of induction oxaliplatin and S-1,
followed by concurrent CRT to 46 Gy with the same
agents did not improve pCR in a randomised phase II
study [38]. Toxicity was significantly increased. These
results are supported by phase II trials where 2 cycles
of oxaliplatin and 5-fluorouracil were followed by
50.4 Gy using the same chemotherapy without any sig-
nificant benefit [39, 40].
In summary, induction chemotherapy is likely to only
increase toxicity with no discernible benefit, and the
choice of concurrent radiosensitizing chemotherapy is
likely to be more important.
Alternative Radiosensitzers
The CROSS regimen chemotherapy used was a devia-
tion from the traditional cisplatin/5-fluorouracil regimen
[41]. Weekly low dose carboplatin and paclitaxel were
novel choices which proved exceptionally well tolerated
in CROSS. Previous attempts to incorporate taxanes into
chemoradiotherapy regimes have had varying results.
Docetaxel and paclitaxel both show activity in phase
I/II settings but may increase toxicity, possibly unac-
ceptably [42–44]. The triple agent arm of the NExT
trial which includes docetaxel will likely answer the
question of whether additional taxanes are useful and
tolerable.
Oxaliplatin with capecitabine is more active in the met-
astatic setting than cisplatin with 5-fluorouracil, has a
more favourable toxicity profile and is easier to adminis-
ter [45]. Recent results from the NEOSCOPE study are
instructive here. This phase II trial randomised patients
following induction chemotherapy with oxaliplatin and
capecitabine to concurrent chemoradiation to 45 Gy, with
either two weekly oxaliplatin-capecitabine or weekly
carboplatin and paclitaxel [46]. Only the carboplatin/
paclitaxel arm passed the prespecified threshold of pCR
of 35%, and will now be used in a phase III setting in
comparison with neoadjuvant chemotherapy.
A retrospective comparison of 215 patients treated in
a single institution showed that carboplatin/paclitaxel
was associated with a better overall survival when com-
pared to cisplatin/irinotecan, cisplatin/5-fluorouracil or
cisplatin/5-fluorouracil/cetuximab [47]. On balance,
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where nCRT is to be used, current data favours the use
of weekly carboplatin and paclitaxel based regimen,
based on its efficacy and toxicity profile.
Toxicity of Neoadjuvant Therapy
Concerns over the added acute toxicity of nCRT com-
pared to chemotherapy alone are legitimate. As such
factors including patient age, performance status and
comorbidities should be carefully considered when
selecting neoadjuvant therapy. Rigorous radiotherapy
quality assurance is now a standard feature in trials
which together with advances in the management of
treatment-related toxicities, improvements in postopera-
tive care and the centralisation of surgery to high-
volume centres, have improved the outlook for cancer
patients treated with multimodality therapy [48]. Data
from the Netherlands pre- and postcentralisation of sur-
gery showed that R0 rates improved by 5%, mortality
fell from 12 to 4% and overall survival at 2 years in-
creased from 38 to 54% [49]. The complicated, multi-
disciplinary care of the patient group means that insti-
tutional differences in surgical technique, wound man-
agement and intensive care protocols make comparisons
between patient groups within trials difficult. However,
this highlights that perhaps the severity of complications
should be reported as well as overall incidence.
A Scandinavian study randomised 181 patients to ei-
ther neoadjuvant CRT or chemotherapy alone (cisplatin/
5-fluorouracil +/− 40 Gy concomitant radiotherapy) with
the purpose of comparing postresection morbidity and
mortality [50•]. They concluded that CRT did not in-
crease the chances of complication, but any complica-
tion was more likely to be severe. CROSS showed no
increase in incidence of complications in the CRT
group, but they did not comment on severity [35].
A small substudy of 40 patients enrolled in a
randomised phase III trial comparing chemotherapy
and CRT examined cardiac function. They found evi-
dence of acute negative effects on systolic and diastolic
function, as recorded on echocardiography and N-termi-
nal Pro-B-Type Natriuretic peptide, in patients undergo-
ing CRT [51]. The clinical relevance of this needs pro-
spective evaluation but shows clear physiological differ-
ences between both regimes.
PET-Directed Neoadjuvant Strategies
As well as the obvious need to stratify future oesopha-
geal studies by tumour subtype, there is a need for
other predictive markers to assess response to treatment.
To date the most studied, for both aspects, has been
18F-flourodeoxyglucose PET-CT.
MUNICON-I trial showed that PET response can be used
to direct further treatment in distal adenocarcinoma of the
oesophagus [52]. A >35% decrease in SUV indicated meta-
bolic response and assessment was done 14 days after day 1 of
cisplatin/5-fluorouracil. Responders continued with treatment
but non-responders proceeded directly to surgery. The results
showed that metabolic responders had not reached median OS
at the time of reporting, whereas non-responders had a median
OS of 25.8 months. This implies that patients who are not
responding to standard induction chemotherapy, according
to PET criteria, can discontinue neoadjuvant therapy and pro-
ceed to surgery without compromise.
The follow-up trial, MUNICON-II, attempted to clarify the
role of salvage nCRT for patients failing to demonstrate a
PET-response following 14 days of cisplatin/5-fluorouracil
based induction chemotherapy. Metabolic responders
(n = 33) continued on 3 months of neoadjuvant chemotherapy
prior to surgical resection whilst the non-responders (n = 23)
received 32 Gy in twice daily 1.6 Gy fractions, 10 fractions
per week, with either concurrent cisplatin or 5-fluorouracil
[53]. The R0 resection rate was 82% in the PET responders
but a lower than expected rate of 70% was observed in the
non-responders, resulting in this primary study endpoint not
being met. One-year PFS rate was significantly higher in re-
sponders (74 vs 57%, P = 0.035) although overall survival
was similar at around 80%. The authors argue that although
salvage nCRT resulted in a major histopathological response
rate in 26% of PET non-responders, long-term clinical out-
comes were not improved. They suggest the aggressive tu-
mour biology of this group is responsible for these results
and that studies exploring alternative approaches, including
the addition of systemically active drugs, are warranted [54].
A reduction in the metabolic activity of a tumour, defined by a
35% decrease in FDG uptake compared to baseline, at day 14
of neoadjuvant chemotherapy has been prospectively validat-
ed as prognostic biomarker [55]. PET responders had a 3-year
survival of 70% compared to 35% for non-responders. In an
exploratory substudy within a phase II study of induction cis-
platin and irinotecan, an SUV reduction of >35% again pre-
dicted for improved outcomes; higher pCR, increased R0,
longer PFS and improved OS (40.2 versus 25.5 months) [56].
Data supporting the use of PET during nCRT is less
convincing, potentially due to false positive results as a
consequence of treatment-induced inflammation or false
negatives due to small volume occult disease [57].
Within the CROSS trial, a substudy of 100 patients
had a repeat PET scan 14 days after commencing
nCRT, the results of which were correlated to the histo-
pathological response as defined by the Mandard score
(no or <10% viable tumour) on the resection specimen.
A median SUV decrease of 30.9% was observed in
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histopathological responders (n = 64) versus 1.7% for
non-responders (n = 36) (P = 0.001). Although the sen-
sitivity of PET in correctly identifying patients with a
his topathological response was 91% using the
predefined cut-off SUV value of 0% (signifying any
decrease in SUV as a positive test result), the specificity
was only 50% [58]. On the basis of these results, FDG-
PET cannot currently be recommended to accurately
identify patients who are not responding nCRT after
2 weeks of treatment. An excellent overview of the
literature by Omloo et al. points out that standardisation
of protocols and minimising inter-institutional differ-
ences is needed before PET-guided treatment can be
routinely adopted for chemoradiation patients [59].
Biological Agents with Chemotherapy
and Chemoradiotherapy
The use of targeted therapies in combination with chemo-
therapy in locally advanced gastrooesophageal adenocar-
cinoma remains investigational. Perioperative cetuximab/
5-fluorouracil did not demonstrate efficacy with 71% of
patients (n = 64) classified as non-responders [60].
Similarly, the addition of neoadjuvant panitumumab to
ECX did not improve the rates of downstaging or pCR
in an AIO phase II study [61]. Bevacizumab and periop-
erative ECX (ECX-B) chemotherapy did not improve sur-
vival outcomes in patients with resectable lower oesoph-
ageal or GOJ adenocarcinoma [62•]. Recently published
in abstract form, the phase III ST03 trial showed similar
rates in both response to preoperative therapy, R0 resec-
tions and 3-year OS (48.9% ECX vs 47.6% ECX + B; OS
HR 1.067) but an increased rate of anastomotic leak fol-
lowing oesophago-gastrectomy in patients receiving ECX-
B (23 vs 9%).
Trastuzumab with cisplatin/5-fluorouracil chemotherapy is
known to improve OS in advancedHER-2 positive gastric and
GOJ tumours [63], and phase II studies have assessed its effi-
cacy in locally advanced gastrooesophageal adenocarcinoma.
pCR rates of more than 20% were achieved using periopera-
tive trastuzumab in combination with FLOT, with 93% of
patients (n = 45) achieving a R0 resection; adverse events
were as expected with this regimen [64]. Perioperative
trastuzumab and XELOX may also have activity with a re-
ported 18 month DFS of 71% [65].
Further modification of chemoradiotherapy with bio-
logical agents appears attractive given their success in
the neighbouring anatomical site of head and neck [66],
in particular agents that target the epidermal growth fac-
tor receptor (EGFR). A phase Ib/II trial of induction
cisplatin, docetaxel and cetuximab followed by 45 Gy
with cisplatin and cetuximab showed acceptable toxicity
with 86% of patient completing therapy and a pCR rate
of 68% and a phase III trial is ongoing [67]. A novel
EGFR inhibitor, nimotuzumab, has been trialled with
cisplatin and CRT (cisplatin and 5-fluorouracil) [68].
In an almost exclusive SCC population, it did not meet
its primary endpoint of endoscopic CR but the addition
of nimotuzumab did significantly improve a secondary
endpoint of combined endoscopic CR and pCR (62.3 vs
33.3%). This regimen may be taken forward for phase
III testing. The addition of panitumumab to cisplatin
and docetaxel augmented radiation resulted in a pCR
rate of 32.8% however, the toxicity profile was signifi-
cant with 23% having grade 4 + toxicity [69]. A small
phase II study of 33 patients adding bevacizumab to
cisplatin and irinotecan modified radiation given in the
neoadjuvant setting found that although the regime was
tolerable there was no suggestion of improvement in
PFS, OS or pCR [70]. The regimen was deemed unsuit-
able for taking forward to the phase III setting.
Conclusions
Rapid developments over the last 15 years in the man-
agement of oesophageal cancer have left many clini-
cians uncertain in how best to proceed. Ongoing trials,
organised according to histological subtype and anatom-
ical location, will help to unravel the uncertainty caused
by the significant heterogeneity of older data.
In summary, the authors would recommend several
key principles of management. Early stage I do tumours
do not benefit from neoadjuvant therapy and should
proceed directly to surgery; locally advanced tumours
will benefit. In SCC, both definitive CRT as well as
tri-modality therapy consisting of nCRT and surgery
are considered as standard options. Both neoadjuvant
chemotherapy and neoadjuvant CRT are treatment op-
tions for oesophageal adenocarcinoma, however, it may
be particularly useful to consider tri-modality treatment
for bulky adenocarcinomas where there is a priori con-
cern about the ability to achieve an R0 margin. In other
situations, neoadjuvant chemotherapy alone can be con-
sidered an acceptable alternative. Decision making may
also not purely be about tumour factors. Baseline pa-
tient factors may also favour one form of neoadjuvant
therapy over another, for example previous “in field”
radiotherapy for another condition may persuade a cli-
nician to use chemotherapy alone. Given the complex
nature of care leading to any given outcome, in partic-
ular survival, we would also recommend institutions
regularly audit their practice to ensure a patient-centred,
evidence-based approach.
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